Lipoprotein (a) in patients with psoriasis: associations with lipid profiles and disease severity

Pietrzak, Aldona; Kadzielewski, Jacek; Janowski, Konrad; Roliński, Jacek; Krasowska, Dorota; Chodorowska, Grażyna; Paszkowski, Tomasz; Kapeć, E; Jastrzębska, Iwona; Tabarkiewicz, Jacek; Lotti, Torello

doi:10.1111/j.1365-4632.2009.03994.x

Cited by 32 publications

(31 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…19 Psoriatic patients also had elevated levels of lipoprotein (a) after controlling for hyperlipidemia. 21 Overall, the preponderance of data supports this association with dyslipidemia.…”

Section: Cvd Risk Factors Associated With Psoriasismentioning

confidence: 59%

Psoriasis and Vascular Disease—Risk Factors and Outcomes: A Systematic Review of the Literature

et al. 2011

View full text Add to dashboard Cite

“…19 Psoriatic patients also had elevated levels of lipoprotein (a) after controlling for hyperlipidemia. 21 Overall, the preponderance of data supports this association with dyslipidemia.…”

Section: Cvd Risk Factors Associated With Psoriasismentioning

confidence: 59%

Psoriasis and Vascular Disease—Risk Factors and Outcomes: A Systematic Review of the Literature

et al. 2011

View full text Add to dashboard Cite

“…Wielu autorów wykazało zwiększo-ne stężenie apolipoprotein (apo A1, apo B, apo C i apo E) w surowicy chorych na łuszczycę [35][36][37]. Niektórzy nie obserwowali zmian w porównaniu z grupą kontrolną [38,39], inni stwierdzili zmniejszenie ich stężenia [34].…”

Section: Lipidy W Surowicy Cholesterole Trójglicerydy I Apolipoproteinyunclassified

“…Many authors have shown elevated concentrations of apolipoproteins (apo A1, apo B, apo C and apo E) in the serum of patients with psoriasis [35][36][37]. Some studies have found no change relative to the control group [38,39], and others have shown a decrease in apolipoprotein levels [34].…”

Section: Lipidy W Surowicy Cholesterole Trójglicerydy I Apolipoproteinymentioning

confidence: 99%

The role of lipids in psoriasis

Baran¹,

Kiluk²,

Myśliwiec³

et al. 2017

View full text Add to dashboard Cite

Psoriasis, affecting 2-4% of the world's population, is a chronic recurrent inflammatory skin disease. Its multifactorial aetiopathogenesis consists of, for example, abnormal epidermal proliferation, immune disturbances, and genetic, psychosomatic, environmental and hormonal factors. Psoriasis is also considered to be a systemic disorder closely associated with cardiovascular diseases, atherosclerosis, diabetes mellitus, obesity or metabolic syndrome. Lipids have a variety of biological functions. They participate not only in energy storage and expenditure or the formation of cell membranes, but also in inflammatory and metabolic signalling pathways. Disturbances in their homeostasis lead to the development of immunometabolic disorders, including psoriasis. Based on the available literature, this article presents selected molecular and clinical aspects involved in the multidirectional effect of lipids on psoriasis.streszczenie Łuszczyca, która występuje u 2-4% populacji na świecie, jest przewlekłą i nawrotową chorobą zapalną skóry. Na jej wieloczynnikową etiopatogenezę składają się m.in. nieprawidłowa proliferacja naskórka, zaburzenia immunologiczne, czynniki genetyczne, psychosomatyczne, środowiskowe i hormonalne. Łuszczyca jest również uznawana za schorzenie ogólnoustrojowe, związane z chorobami układu sercowo--naczyniowego, miażdżycą, cukrzycą, otyłością i zespołem metabolicznym. Lipidy pełnią wiele biologicznych funkcji, biorą udział nie tylko w magazynowaniu i wydatkowaniu energii, tworzeniu błon komórko-wych, lecz także w zapalnych i metabolicznych szlakach sygnałowych. Zaburzenia ich homeostazy powodują rozwój schorzeń immunometabolicznych, w tym łuszczycy. W niniejszej pracy przedstawiono na podstawie dostępnego piśmiennictwa wybrane aspekty molekularne i kliniczne wielokierunkowego wpływu lipidów na łuszczycę.

show abstract

“…In most studies, elevated levels of apoA1, apoB [16, 43], apoC3, and apoE [41, 76–78] were detected in the serum of psoriatic patients compared to the healthy control group. However, there are also contrary results showing decreased levels of apolipoproteins [79].…”

Section: Apolipoproteinsmentioning

confidence: 99%

Lipid Disturbances in Psoriasis: An Update

Pietrzak

Michalak-Stoma

Chodorowska

et al. 2010

Mediators of Inflammation

Self Cite

123

109

View full text Add to dashboard Cite

Psoriasis is a common disease with the population prevalence ranging from 2% to 3%. Its prevalence in the population is affected by genetic, environmental, viral, infectious, immunological, biochemical, endocrinological, and psychological factors, as well as alcohol and drug abuse. In the recent years, psoriasis has been recognised as a systemic disease associated with numerous multiorgan abnormalities and complications. Dyslipidemia is one of comorbidities in psoriatic patients. Lipid metabolism studies in psoriasis have been started at the beginning of the 20th century and are concentrated on skin surface lipids, stratum corneum lipids and epidermal phospholipids, serum lipids, dermal low-density lipoproteins in the psoriatic skin, lipid metabolism, oxidative stress and correlations between inflammatory parameters, lipid parameters and clinical symptoms of the disease. On the basis of the literature data, psoriasis can be described as an immunometabolic disease.

show abstract

Lipoprotein (a) in patients with psoriasis: associations with lipid profiles and disease severity

Abstract: Lp(a) may be a factor contributing to an increased cardiovascular risk in patients with psoriasis. A pathogenetic link may exist between this lipoprotein and psoriatic pathophysiology.

Cited by 32 publications

References 63 publications

Psoriasis and Vascular Disease—Risk Factors and Outcomes: A Systematic Review of the Literature

Psoriasis and Vascular Disease—Risk Factors and Outcomes: A Systematic Review of the Literature

The role of lipids in psoriasis

Lipid Disturbances in Psoriasis: An Update

Contact Info

Product

Resources

About